Form 8-K IONIS PHARMACEUTICALS For: Feb 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Cerebras Systems hits new 52-week low on unlock concerns
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
Ionis Pharma (IONS) Tops Q4 EPS by 1c
February 27, 2018 6:23 AM ESTIonis Pharma (NASDAQ: IONS) reported Q4 EPS of $0.02, $0.01 better than the analyst estimate of $0.01. Revenue for the quarter came in at $172.3 million versus the consensus estimate of $124.69 million.
For earnings history and earnings-related data on Ionis Pharma (IONS) click here.
... More


